Tresiba® FlexTouch® comes in 2 dose formulations: U-100 and U-200


  • Pen contains 300 total units
  • No push-button extension
  • 1-unit dose adjustments
  • Delivers up to 80 units in a single injection1
Tresiba® FlexTouch® U-100 dosing window showing 80 units


Tresiba® FlexTouch® U-200 dosing window showing 160 units
  • Pen contains 600 total units
  • No push-button extension
  • 2-unit dose adjustments
  • Delivers up to 160 units in a single injection1


After opening, Tresiba® may be used for up to 8 weeks when kept at room temperature or in the refrigerator vs 4 weeks for insulin glargine U-100 and 6 weeks for insulin glargine U-3001-3,a,b

The dose window for both the Tresiba® U-100 and U-200 FlexTouch® pens shows the number of insulin units to be delivered, and NO conversion is needed1

aOpened (in-use) Tresiba® FlexTouch® should be refrigerated (36°F to 46°F [2°C to 8°C]) or kept at room temperature (below 86°F [30°C]), away from direct heat and light.1

bOpened (in-use) Lantus® and Toujeo® SoloSTAR® devices must be discarded 4 weeks (Lantus®) or 6 weeks (Toujeo®) after being opened.2,3


Watch the Instructions For Use video and see how to get your patients started on once-daily dosing


Log in or register to request samples of Tresiba®


You must be a licensed practitioner who can legally prescribe medication in your state. (Request for product samples is limited to 1 request per health care professional.)


Once-daily Tresiba®: When schedules change, dose timing for adults can too

Continued efficacy for your adult patients even if a dose is delayed or schedules change1

Four people who wish to adjust their dosing time with Tresiba®

Adult patients who miss a dose of Tresiba® should inject their daily dose during waking hours upon discovering the missed dose, then continue with their regular dosing schedule. Ensure that at least 8 hours have elapsed between Tresiba® injections.1    


Only Tresiba® U-200 FlexTouch® delivers the same dose in half the volume of insulin glargine U-1001,2

Graphic showing Tresiba® u-200 Flextouch® delivers the same dose in half the volume of insulin glargine 100 u/mL

For illustrative purposes only.



Access support for you and your patients



Discover the latest professional resources from Tresiba®
Eligible patients pay as little as $15 per prescriptionc

cFor up to 24 months. Maximum savings of $500 per prescription. Eligibility and other restrictions apply.

Selected Important Safety Information

Contraindications

  • Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients

Warnings and Precautions

  • Never Share a Tresiba® FlexTouch® Pen Between Patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens
  • Monitor blood glucose in all patients treated with insulin. Changes in insulin may affect glycemic control. These changes should be made cautiously and under medical supervision. Adjustments in concomitant oral anti-diabetic treatment may be needed
  • Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening

Indications and Usage

Tresiba® (insulin degludec injection) is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.

Limitations of Use

Tresiba® is not recommended for treating diabetic ketoacidosis or for pediatric patients requiring less than 5 units of Tresiba®.

Important Safety Information

Contraindications

  • Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients

Warnings and Precautions

  • Never Share a Tresiba® FlexTouch® Pen Between Patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens
  • Monitor blood glucose in all patients treated with insulin. Changes in insulin may affect glycemic control. These changes should be made cautiously and under medical supervision. Adjustments in concomitant oral anti-diabetic treatment may be needed
  • Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening. Increase monitoring with changes to: insulin dose, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with hypoglycemia unawareness or renal or hepatic impairment
  • Accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors, always instruct patients to check the insulin label before each injection
  • Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including Tresiba®
  • As with all insulins, Tresiba® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated
  • Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including Tresiba®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered

Adverse Reactions

  • Adverse reactions commonly associated with Tresiba® are hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema, and weight gain

Drug Interactions

  • Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs and symptoms of hypoglycemia may be reduced or absent in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine)

Please click here for Prescribing Information.

 

References:

  1. Tresiba [package insert]. Plainsboro, NJ: Novo Nordisk Inc; December 2016.
  2. Lantus [package insert]. Bridgewater, NJ: sanofi-aventis US LLC; August 2015.
  3. Toujeo [package insert]. Bridgewater, NJ: sanofi-aventis US LLC; September 2015.